Related Experiment Video
Updated: Aug 6, 2026
15:57
Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
Published on: July 11, 2015
Bovine serum--regulatory issues
1Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. jrobertson@nibsc.ac.uk
Developments in Biologicals
|March 29, 2006
Summary
Ensuring viral safety in bovine serum for biological products is crucial. Recent EU guidelines focus on infectious bovine polyoma virus and BVDV, but recommendations are relaxing, emphasizing risk analysis for overall serum safety.
Area of Science:
- Biologics Manufacturing
- Regulatory Science
- Veterinary Medicine
Background:
- USDA 9CFR historically ensured viral safety of bovine serum for biological products.
- EU regulators have issued new guidelines and the European Pharmacopoeia a monograph on bovine serum use.
- Harmonization exists, but EU CHMP guidelines highlight infectious bovine polyoma virus and BVDV antibody detection.
Purpose of the Study:
- To analyze the evolving regulatory landscape for bovine serum in biological product manufacturing.
- To discuss the implications of EU guidelines on viral safety assessments.
- To advocate for a risk-based approach to ensure overall viral safety of bovine serum.
Main Methods:
- Review of current USDA and EU regulations and guidelines.
- Analysis of pharmacopoeial standards for bovine serum.
- Discussion of viral safety testing methodologies and risk assessment principles.
Main Results:
- EU guidelines emphasize infectious bovine polyoma virus and BVDV antibody detection.
- Regulatory stringency is being relaxed following industry feedback.
- A comprehensive risk analysis is essential for managing undetected viral contamination.
Conclusions:
- Overall viral safety of bovine serum requires a risk-based approach, considering geographical source, inactivation efficacy, and cell culture susceptibility.
- While regulations evolve, the inherent presence of viruses necessitates ongoing vigilance.
- Balancing regulatory demands with practical risk management is key for safe biological product manufacturing.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...